Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BARICIVID-19 STUDY: MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy

NCT04393051 is registered in ClinicalTrials.gov with Azienda Ospedaliero, Universitaria Pisana as lead sponsor.

NCT NCT04393051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04393051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BARICIVID-19 STUDY: MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Phase
Phase 2
Overall status
Unknown status
Start date
May 20, 2020
Completion date
July 30, 2020
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars pneumonia, sars-cov 2